Korea Joongang Daily on MSN1h
Celltrion's Actemra biosimilar gets FDA approvalCelltrion's biosimilar Avtozma, used to treat inflammatory diseases, was approved for the U.S. market by the Food and Drug Administration.
Celltrion Inc., a major South Korean biopharmaceutical firm, said Friday its new biosimilar for an autoimmune disease treatment has received approval from the U.S. Food and Drug Administration (FDA).
As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...
US biotech major Amgen =announced that it has reached resolution of its patent infringement litigation related to South Korea ...
The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.
On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...
An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...
South Korea’s Celltrion has made its first major acquisition, buying a portfolio of drugs including diabetes and hypertension drugs from Takeda that will expand its expertise with small ...
Celltrion unveils strategic roadmap for the first time outlining its innovative drug development strategy and its plan to submit 13 Investigational New Drug (IND) application by 2028 Company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback